Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1.

Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM.

Respir Res. 2019 Jul 18;20(1):159. doi: 10.1186/s12931-019-1119-6.

2.

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.

Vogelberg C, Szefler SJ, Vrijlandt EJLE, Boner AL, Engel M, El Azzi G, Vulcu SD, Moroni-Zentgraf PM, Eickmeier O, Hamelmann EH.

Eur Respir J. 2019 Jun 13;53(6). pii: 1801824. doi: 10.1183/13993003.01824-2018. Print 2019 Jun.

3.

Inhalation Devices.

Moroni-Zentgraf P, Usmani OS, Halpin DMG.

Can Respir J. 2018 Sep 18;2018:5642074. doi: 10.1155/2018/5642074. eCollection 2018. No abstract available.

4.

Pharmacokinetics of tiotropium in asthmatic children aged 6-11 years support its safety profile.

Sharma A, Aalbers R, Hamelmann E, Goldstein S, Engel M, Moroni-Zentgraf P, Vogelberg C.

Pediatr Allergy Immunol. 2018 Nov;29(7):773-776. doi: 10.1111/pai.12952. Epub 2018 Sep 3. No abstract available.

PMID:
29972697
5.

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma.

Vogelberg C, Engel M, Laki I, Bernstein JA, Schmidt O, El Azzi G, Moroni-Zentgraf P, Sigmund R, Hamelmann E.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2160-2162.e9. doi: 10.1016/j.jaip.2018.04.032. Epub 2018 May 8. No abstract available.

6.

Efficacy of tiotropium in adults with moderate asthma, by leukotriene receptor antagonist use at baseline.

Hashimoto S, Casale TB, Engel M, Moroni-Zentgraf P, Bour LJ, Kerstjens HAM.

Allergol Int. 2018 Jul;67(3):411-413. doi: 10.1016/j.alit.2017.12.002. Epub 2018 Feb 15. No abstract available.

7.

Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.

Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, Szefler SJ, Moroni-Zentgraf P, Sharma A, Vulcu SD, Sigmund R, Chawes B, Engel M, Bisgaard H.

Lancet Respir Med. 2018 Feb;6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18.

PMID:
29361462
8.

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.

Casale TB, Bateman ED, Vandewalker M, Virchow JC, Schmidt H, Engel M, Moroni-Zentgraf P, Kerstjens HAM.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):923-935.e9. doi: 10.1016/j.jaip.2017.08.037. Epub 2017 Nov 22.

9.

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.

Szefler SJ, Murphy K, Harper T 3rd, Boner A, Laki I, Engel M, El Azzi G, Moroni-Zentgraf P, Finnigan H, Hamelmann E.

J Allergy Clin Immunol. 2017 Nov;140(5):1277-1287. doi: 10.1016/j.jaci.2017.01.014. Epub 2017 Feb 9.

10.

Pharmacokinetics of tiotropium administered by Respimat® in asthma patients: Analysis of pooled data from Phase II and III clinical trials.

Sharma A, Kerstjens HA, Aalbers R, Moroni-Zentgraf P, Weber B, Dahl R.

Pulm Pharmacol Ther. 2017 Feb;42:25-32. doi: 10.1016/j.pupt.2016.12.003. Epub 2016 Dec 28.

PMID:
28039077
11.

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.

Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, Engel M, Boner AL.

Eur Respir J. 2017 Jan 11;49(1). pii: 1601100. doi: 10.1183/13993003.01100-2016. Print 2017 Jan.

12.

Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.

Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED.

Respir Med. 2016 Sep;118:102-111. doi: 10.1016/j.rmed.2016.07.001. Epub 2016 Jul 2.

13.

Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.

Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED.

Respir Med. 2016 Aug;117:198-206. doi: 10.1016/j.rmed.2016.06.013. Epub 2016 Jun 14.

14.

Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.

Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, Avis M, Unseld A, Engel M, Boner AL.

J Allergy Clin Immunol. 2016 Aug;138(2):441-450.e8. doi: 10.1016/j.jaci.2016.01.011. Epub 2016 Mar 5.

15.

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.

16.

Tiotropium add-on therapy in patients with uncontrolled asthma.

Kerstjens HA, Moroni-Zentgraf P.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1553. doi: 10.5588/ijtld.15.0409. No abstract available.

PMID:
26614202
17.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E.

J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13.e2. doi: 10.1016/j.jaip.2015.08.017. Epub 2015 Nov 7.

18.

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.

Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S.

Respir Res. 2015 Oct 20;16:128. doi: 10.1186/s12931-015-0290-7. No abstract available.

19.

Bronchodilator reversibility and cardiac considerations with use of tiotropium.

Kerstjens HA, Moroni-Zentgraf P.

Lancet Respir Med. 2015 Aug;3(8):e25-6. doi: 10.1016/S2213-2600(15)00257-X. No abstract available.

PMID:
26282477
20.

In Vitro Determination of Respimat® Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth-Throat Models.

Bickmann D, Kamin W, Sharma A, Wachtel H, Moroni-Zentgraf P, Zielen S.

J Aerosol Med Pulm Drug Deliv. 2016 Feb;29(1):76-85. doi: 10.1089/jamp.2014.1166. Epub 2015 Jun 22.

21.

Tiotropium in asthma - Authors' reply.

Kerstjens HA, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):e17. doi: 10.1016/S2213-2600(15)00105-8. No abstract available.

PMID:
25969363
22.

Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis.

Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, FitzGerald JM.

J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023. Epub 2015 May 1. Review.

23.

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.

Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M.

PLoS One. 2015 Apr 20;10(4):e0124109. doi: 10.1371/journal.pone.0124109. eCollection 2015.

24.

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.

Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S.

Respir Res. 2015 Feb 7;16:20. doi: 10.1186/s12931-015-0175-9. Erratum in: Respir Res. 2015;16:128.

25.

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old.

Kamin W, Frank M, Kattenbeck S, Moroni-Zentgraf P, Wachtel H, Zielen S.

J Aerosol Med Pulm Drug Deliv. 2015 Oct;28(5):372-81. doi: 10.1089/jamp.2014.1159. Epub 2015 Apr 6.

26.

Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.

Ratjen F, Koker P, Geller DE, Langellier-Cocteaux B, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

J Cyst Fibros. 2015 Sep;14(5):608-14. doi: 10.1016/j.jcf.2015.03.004. Epub 2015 Mar 26.

27.

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12.

PMID:
25682232
28.

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.

Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27.

29.

Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.

Konstan MW, Sharma A, Moroni-Zentgraf P, Wang F, Koker P.

J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):137-44. doi: 10.1089/jamp.2013.1115. Epub 2014 Nov 7.

PMID:
25380193
30.

Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results.

Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

PLoS One. 2014 Sep 4;9(9):e106195. doi: 10.1371/journal.pone.0106195. eCollection 2014.

31.

Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.

Sharma A, Geller DE, Moroni-Zentgraf P, Kattenbeck S, Schmid M, Boland K, Rapp B, Konstan MW, Ratjen F, Elborn JS, Koker P.

Pulm Pharmacol Ther. 2014 Dec;29(2):217-23. doi: 10.1016/j.pupt.2014.08.004. Epub 2014 Aug 24.

PMID:
25161072
32.

Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.

Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, Nething K, Vevere V, Vandewalker M.

Respir Med. 2014 Sep;108(9):1268-76. doi: 10.1016/j.rmed.2014.06.011. Epub 2014 Jul 17.

33.

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.

34.

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.

Respir Med. 2013 Jun;107(6):854-62. doi: 10.1016/j.rmed.2013.02.005. Epub 2013 Mar 13.

35.

Tiotropium in asthma poorly controlled with standard combination therapy.

Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED.

N Engl J Med. 2012 Sep 27;367(13):1198-207. Epub 2012 Sep 2.

Supplemental Content

Loading ...
Support Center